Should You Buy OptimizeRx Corp (OPRX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
OptimizeRx Corp (OPRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth and positive analyst sentiment, the technical indicators are bearish, and the stock has recently seen a slight decline in price. Additionally, the lack of significant positive trading signals and the company's declining net income and EPS suggest caution. The investor may consider waiting for a more favorable entry point or stronger signals before investing.
Technical Analysis
The technical indicators for OPRX are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 36.647, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 11.659), with resistance levels at R1: 13.737 and R2: 14.379.
Analyst Ratings and Price Target Trends
Analyst sentiment is positive overall. Recent updates include multiple firms raising price targets (e.g., Roth Capital to $32, Lake Street to $24, and B. Riley to $28) and maintaining Buy ratings. Analysts highlight strong Q3 performance, improved guidance, and expectations for double-digit growth.
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.33 USD with a low forecast of 17 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.33 USD with a low forecast of 17 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 10.970
Current: 10.970
